School of Nursing, Midwifery & Social Work, University of Manchester, Room 5.310, Jean McFarlane Building, University Place, Oxford Road, Manchester, M13 9PL, UK.
Future Oncol. 2013 Oct;9(10):1443-50. doi: 10.2217/fon.13.155. Epub 2013 Aug 29.
This study aimed to determine how aprepitant affects the impact of chemotherapy-induced nausea and vomiting (CINV) on daily activities during highly emetogenic chemotherapy (HEC) or moderately emetogenic chemotherapy (MEC).
PATIENTS & METHODS: Patients received aprepitant plus standard antiemetic therapy (ondansetron plus dexamethasone) or standard antiemetic therapy alone. Data were analyzed from pooled data of two Phase III randomized, double-blind HEC trials and one MEC trial. Patients completed the Functional Living Index-Emesis questionnaire.
A significantly greater percentage of patients receiving aprepitant reported no or minimal CINV impact on daily life (overall total Functional Living Index-Emesis score >6) compared with those receiving standard therapy alone (HEC: 74.4 vs 63.9%, respectively; p < 0.01; MEC: 73.4 vs 66.3%; p < 0.05). In HEC, favorable responses to aprepitant treatment persisted in nausea (70.2 vs 60.9%) and vomiting domains (84.6 vs 68.7%; both p < 0.01). Similar results were seen in MEC.
Addition of aprepitant reduced CINV impact on daily life compared with standard antiemetic therapy.
本研究旨在确定阿瑞匹坦如何影响高度致吐性化疗（HEC）或中度致吐性化疗（MEC）期间化疗引起的恶心和呕吐（CINV）对日常生活的影响。
患者接受阿瑞匹坦加标准止吐治疗（昂丹司琼加地塞米松）或标准止吐治疗单独。数据来自两项 III 期随机、双盲 HEC 试验和一项 MEC 试验的汇总数据进行分析。患者完成功能性生活指数-呕吐问卷。
与单独接受标准治疗的患者相比，接受阿瑞匹坦治疗的患者报告 CINV 对日常生活（总体功能性生活指数-呕吐评分>6）无影响或影响极小的比例显著更高（HEC：分别为 74.4%和 63.9%；p<0.01；MEC：73.4%和 66.3%；p<0.05）。在 HEC 中，阿瑞匹坦治疗在恶心（70.2%比 60.9%）和呕吐领域（84.6%比 68.7%；均 p<0.01）的反应良好。在 MEC 中也观察到类似的结果。
与标准止吐治疗相比，阿瑞匹坦的添加减少了 CINV 对日常生活的影响。
